Antitumor effect of vandetanib through EGFR inhibition in head and neck squamous cell carcinoma
about
Genomic Correlate of Exceptional Erlotinib Response in Head and Neck Squamous Cell Carcinoma.Treatment of recurrent metastatic head and neck cancer: focus on cetuximab.Cortactin expression confers a more malignant phenotype to gastric cancer SGC-7901 cells.The anti-neoplastic activity of Vandetanib against high-risk medulloblastoma variants is profoundly enhanced by additional PI3K inhibitionPER1 and CLOCK: potential circulating biomarkers for head and neck squamous cell carcinoma.
P2860
Antitumor effect of vandetanib through EGFR inhibition in head and neck squamous cell carcinoma
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Antitumor effect of vandetanib ...... d neck squamous cell carcinoma
@en
type
label
Antitumor effect of vandetanib ...... d neck squamous cell carcinoma
@en
prefLabel
Antitumor effect of vandetanib ...... d neck squamous cell carcinoma
@en
P2093
P2860
P356
P1433
P1476
Antitumor effect of vandetanib ...... d neck squamous cell carcinoma
@en
P2093
Apostolos Christopoulos
Jonah D Klein
Seungwon Kim
William E Gooding
P2860
P304
P356
10.1002/HED.21917
P577
2012-02-06T00:00:00Z